Mariya Rozenblit, MD
Assistant Professor of Medicine (Medical Oncology)Cards
About
Titles
Assistant Professor of Medicine (Medical Oncology)
Biography
Dr. Mariya Rozenblit is an Assistant Professor of Medicine in the section of Medical Oncology and cares for patients with a clinical focus on breast cancer. She completed her Fellowship in Medical Oncology-Hematology at Yale, Residency in Internal Medicine at NYU, and received her medical degree from Icahn School of Medicine. She is involved in educating medical students, residents, and fellows at Yale. Outside of the clinic, her focus is translational research with an interest in biomarker driven trial development in breast cancer.
In 2020, she was the recipient of the ASCO Conquer Cancer Foundation Young Investigator Award for her project, “Using single nucleotide variants of high functional importance to predict the risk of developing breast cancer in young women with high risk family history.” This award is for promising investigators to encourage and promote quality research in clinical oncology. In 2022, she was the recipient of the Susan G. Komen Career Catalyst Research Grant for her project, "Curing de novo oligometastatic HER2+ breast cancer". This grant is to foster promising breast cancer researchers by providing support for up to three years.
Appointments
Medical Oncology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- Internal Medicine Resident
- NYU Langone Medical Center (2018)
- MD
- Icahn School of Medicine at Mount Sinai (2015)
- BA
- Columbia University, Biology (2009)
Research
Publications
2024
Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history
Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Research And Treatment 2024, 1-6. PMID: 39602012, DOI: 10.1007/s10549-024-07560-y.Peer-Reviewed Original ResearchHigh-risk family historyFamily historyRare germline variantsCancer riskSNP-set kernel association testAssociated with breast cancer riskCancer casesContribution of family historyEarly-onset breast cancerCancer Prevention ClinicBreast cancerBreast cancer riskKernel association testBreast cancer casesCancer-predisposing genesGermline variantsGermline pathogenic variantsYoung womenPrevention clinicSKAT-OBurden testsPathogenic variantsExome sequencing dataAssociation TestLevel alterations
2023
Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study
Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.Peer-Reviewed Original ResearchComprehensive genomic profilingBreast cancerYoung womenGenomic alterationsAdvanced breast cancerPD-L1 expressionTargetable genomic alterationsWorse clinical outcomesTime of diagnosisTumor mutational burdenCross-sectional studyBreast cancer casesFoundation MedicineClinical outcomesPIK3CA mutationsCancer casesEstrogen receptorMutational burdenOlder womenConclusionOur findingsTotal casesBreast tumorsTumor tissueBRCA1 mutationsMicrosatellite instabilityMolecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.Peer-Reviewed Original ResearchConceptsHER2 mRNA levelsIHC 0MRNA levelsOncotype DX recurrence score resultsEstrogen receptor-positive breast cancerReceptor-positive breast cancerCurrent adjuvant chemotherapyOncotype DX assayRecurrence Score resultsPositive breast cancerInvasive breast carcinomaIHC score 0Adjuvant chemotherapyQuantitative RT-PCRBreast carcinomaPositive statusScore 0Breast cancerStage IYale cohortHigher mRNA levelsCancerRT-PCRPatientsHER2De Novo Oligometastatic Breast Cancer
Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2023, 41: 5237-5241. PMID: 37607325, PMCID: PMC10691789, DOI: 10.1200/jco.23.00911.Peer-Reviewed Original ResearchMore than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome
Minteer C, Thrush K, Gonzalez J, Niimi P, Rozenblit M, Rozowsky J, Liu J, Frank M, McCabe T, Sehgal R, Higgins-Chen A, Hofstatter E, Pusztai L, Beckman K, Gerstein M, Levine M. More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome. Science Advances 2023, 9: eadf4163. PMID: 37467337, PMCID: PMC10355820, DOI: 10.1126/sciadv.adf4163.Peer-Reviewed Original ResearchConceptsStem cell divisionImmortalized human cellsTissue-specific cancer riskTumorigenic stateCell divisionDNA methylationEpigenetic changesAge-related accumulationHuman cellsMultiple tissuesSomatic mutationsClinical tissuesTissue differencesEpigenomeCellsTissueNormal tissuesMethylationMutationsReplicationNormal breast tissueSignaturesVitroAccumulationDivision
2022
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.Peer-Reviewed Original ResearchBreast cancerYounger patientsHER2-negative breast cancerNode-positive breast cancerNode-negative diseaseSame clinical featuresHigh mutation burdenLower mRNA expressionAdjuvant chemotherapyMicroarray cohortTAILORx trialOvarian suppressionOlder patientsPatient ageClinical featuresProliferation-related gene expressionScore 0Mutation burdenCopy number gainsOlder womenGATA3 mutationsAge groupsGene signatureMRNA expressionChemotherapyPD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer
Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Research And Treatment 2022, 196: 221-227. PMID: 36028784, DOI: 10.1007/s10549-022-06712-2.Peer-Reviewed Original ResearchConceptsPD-L1 positivityPD-L1 protein expressionPD-L1 expressionGrade 3 cancersPD-L1TIL scoreTumor gradeMultivariate analysisHigher PD-L1 positivityTumor-infiltrating lymphocyte countsConclusionPD-L1 expressionProtein expressionPD-L1 immunohistochemistryChi-square testResultsPD-L1T1 cancersLymphocyte countT3 tumorsIndependent predictorsTumor sizeLarge tumorsPositivity rateCell positivityBreast cancerGrade 2Targetable genomic mutations in young women with advanced breast cancer.
Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Targetable genomic mutations in young women with advanced breast cancer. Journal Of Clinical Oncology 2022, 40: 1027-1027. DOI: 10.1200/jco.2022.40.16_suppl.1027.Peer-Reviewed Original ResearchComprehensive genomic profilingTumor mutational burdenAdvanced breast cancerPD-L1 expressionBreast cancerYoung womenImmune therapyPIK3CA mutationsGenomic alterationsTumor cell PD-L1 expressionClasses of GAsRB1 mutationsDisease-free survivalActionable genomic alterationsDifferent mutational profilesPARP inhibitor useImmunotherapy optionsInhibitor useFoundation MedicineLymph nodesWorse prognosisBRCA2 mutationsEstrogen receptorMutational burdenOlder womenCancer Relevance of Human Genes
Qing T, Mohsen H, Cannataro VL, Marczyk M, Rozenblit M, Foldi J, Murray M, Townsend J, Kluger Y, Gerstein M, Pusztai L. Cancer Relevance of Human Genes. Journal Of The National Cancer Institute 2022, 114: 988-995. PMID: 35417011, PMCID: PMC9275765, DOI: 10.1093/jnci/djac068.Peer-Reviewed Original ResearchConceptsCore cancer genesHuman genesFunctional importanceSomatic mutation frequencySelection pressureGene/protein networksCancer genesHigher somatic mutation frequencyNegative selection pressureGene-gene interaction networksMutation frequencyProtein-truncating variantsGenomic contextCell viabilityGenes decreasesCancer Genome AtlasInteraction networksProtein networkCancer relevanceCancer cell viabilityCell survivalGenesCancer biologyGenome AtlasSearch toolsPredictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.Peer-Reviewed Original ResearchConceptsBasal-like triple-negative breast cancerPathologic complete responseResidual diseaseNeoadjuvant durvalumabDNA damage repairSomatic mutationsBreast cancerWnt/β-cateninHigh expressionTriple-negative breast cancerBasal-Like TripleDoxorubicin/cyclophosphamideDNA repairTumor mutation burdenRNA sequencingEpithelial-mesenchymal transitionFive-gene signatureB-cell markersCancer driversEnrichment analysisNegative breast cancerDamage repairGene expressionJAK-STATCell cycle
Clinical Trials
Current Trials
2000033529: A pilot study to evaluate biomarkers and safety of dapagliflozin concomitant with neoadjuvant therapy for patient with HER2-negative early-stage breast cancer and hyperinsulinemia (previously HIC 2000031461) [Yale HIC]
HIC ID2000033529RoleSub InvestigatorPrimary Completion Date12/31/2025Recruiting ParticipantsUse of DiviTum -TKa as a biomarker assay for CDK4/6 inhibitor medication compliance and drug-drug interactions assessment and intervention in HR-positive metastatic breast cancer patients
HIC ID2000033797RolePrincipal InvestigatorPrimary Completion Date05/03/2025Recruiting ParticipantsPhase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
HIC ID2000033661RoleSub InvestigatorPrimary Completion Date09/30/2024Recruiting ParticipantsA Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
HIC ID2000033838RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting ParticipantsGenderBothAge50 years - 70 yearsAn observational study of circulating tumor DNA in triple negative breast cancers with residual disease after standard neoadjuvant treatment.
HIC ID2000033096RolePrincipal InvestigatorPrimary Completion Date12/31/2025Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Mariya Rozenblit, MD, is a medical oncologist who specializes in treating patients with different types of breast cancer, from ductal carcinoma in situ (DCIS), the most common type of breast cancer, to metastatic breast cancer, or stage IV breast cancer.
Dr. Rozenblit research focuses on biomarker-driven trial development in breast cancer. These types of clinical trials allow researchers to investigate how patients (including those with different cancer mutations) respond to available medications. For example, Dr. Rozenblit co-authored a study that found patients younger than 40 with advanced breast cancer often suffer a worse prognosis and more severe symptoms than older patients.
She has received the American Society of Clinical Oncology’s Conquer Cancer Foundation’s Young Investigator Award and the Susan G. Komen Cancer Catalyst Research Grant. Dr. Rozenblit is an assistant professor of medicine (medical oncology) at Yale School of Medicine.
Clinical Specialties
Medical Oncology
Fact Sheets
Breast Cancer
Learn More on Yale MedicineCancer
Learn More on Yale MedicineDiagnosing Cancer
Learn More on Yale MedicineInflammatory Breast Cancer
Learn More on Yale Medicine
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2018
Yale Medicine News
News & Links
News
- December 17, 2024
Yale Cancer Center presents advances in breast cancer at the San Antonio Breast Cancer Symposium
- December 13, 2024Source: OncLive
Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer
- November 26, 2024
Advancing Breast Cancer Research: Yale Cancer Center to Share Insights at International Conference
- October 07, 2024
Caring for Metastatic Breast Cancer: A Conference for Patients and Caregivers